| BM | Bachelor of Medicine; barium meal; basal medium; basal metabolism; basement membrane; basilar membra... |
|---|---|
| B/M | black male |
| bm | black male |
| HM | hand movements; health maintenance; heart murmur; hemifacial microsomia; Holter monitoring; home man... |
| IMP | idiopathic myeloid proliferation; impression; incomplete male pseudohermaphroditism; individual Medi... |
| infertility, male | Inability of the male to effect conception. (12 Dec 1998) |
|---|---|
| internal male genital organs | The internal masculine genital organs, the testes, epididymides, deferent ducts, seminal vesicles, prostate, and bulbourethral glands. Synonym: organa genitalia masculina interna. (05 Mar 2000) |
| tuberculosis, male genital | Tuberculosis of the genitalia in men. (12 Dec 1998) |
| external male genital organs | The external masculine genital organs, the penis and scrotum. Synonym: organa genitalia masculina externa. (05 Mar 2000) |
| fertility agents, male | Compounds which increase the capacity of the male to induce conception. (12 Dec 1998) |
| urethral crest of male | A longitudinal fold on the posterior wall of the urethra extending from the uvula of the bladder through the prostatic urethra; prominent in its midportion is the seminal colliculus. Synonym: crista phallica, crista urethralis masculinae. (05 Mar 2000) |
| urologic and male genital diseases | A collective term for urinary tract diseases in male and female and diseases of the male genitalia. (12 Dec 1998) |
| urologic surgical procedures, male | Surgery performed on the male genitalia. (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |